Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China.
J Ethnopharmacol. 2013 Mar 27;146(2):433-9. doi: 10.1016/j.jep.2013.01.029. Epub 2013 Jan 29.
ETHNOPHARMACOLOGICAL RELEVANCE: Chronic gastritis is a very common disease of the digestive tract. Although herbal preparation Chaihu-Shugan-San (CSS) has been widely used as an alternative treatment for chronic gastritis in East Asia, its effectiveness is not verified. The purpose of this meta-analysis is to evaluate the effectiveness of CSS in treating various types of chronic gastritis. MATERIALS AND METHODS: Retrospective review of pertinent literature via Embase, China National Knowledge Infrastructure database, Wanfang Data, Vip Information and the Cochrane Library search using the keywords "Chaihushugan" or "Chaihu Shugan" or "Chai Hu Shu Gan" or "Chaihu Shu Gan". Twenty-one trials were identified including 2572 patients (1384 in CSS group and 1188 in chemotherapy group). Each trial was independently reviewed by two assessors. RESULTS: The risk ratios of bile reflux gastritis, chronic superficial gastritis, chronic atrophic gastritis, and chronic erosive gastritis in the CSS-treated and chemotherapy groups were 1.30, 1.20, 1.24, and 1.48, respectively. CSS had more therapeutic effect in various types of chronic gastritis patients for improving clinical response compared with the chemotherapy group. Of the 21 trials administrating CSS to patients, no adverse event was reported. CONCLUSIONS: CSS was more effective compared to chemotherapy in the treatment of chronic gastritis and no serious side-effects were identified. However, the evidence is insufficient because of the low methodological quality of the included trials. More full-scale, randomized, double-blind, placebo-controlled clinical trials are recommended to further evaluate the therapeutic benefit of CSS.
民族药理学相关性:慢性胃炎是一种非常常见的消化道疾病。虽然草药制剂柴胡疏肝散(CSS)已在东亚被广泛用作慢性胃炎的替代治疗方法,但它的疗效尚未得到验证。本荟萃分析的目的是评估 CSS 治疗各种类型慢性胃炎的疗效。
材料和方法:通过 Embase、中国知网数据库、万方数据、维普信息和 Cochrane 图书馆检索,使用关键词“柴胡疏肝”或“柴胡疏肝”或“柴胡疏肝”或“柴胡疏肝”进行相关文献的回顾性分析。共确定了 21 项试验,包括 2572 例患者(CSS 组 1384 例,化疗组 1188 例)。每个试验均由两名评估员独立进行审查。
结果:CSS 治疗组和化疗组胆汁反流性胃炎、慢性浅表性胃炎、慢性萎缩性胃炎和慢性糜烂性胃炎的风险比分别为 1.30、1.20、1.24 和 1.48。与化疗组相比,CSS 对改善临床反应的各种类型慢性胃炎患者更有效。在 21 项给予 CSS 治疗的试验中,未报告不良事件。
结论:与化疗相比,CSS 治疗慢性胃炎更有效,且未发现严重的副作用。然而,由于纳入试验的方法学质量较低,证据不足。建议进行更多的全面、随机、双盲、安慰剂对照临床试验,以进一步评估 CSS 的治疗益处。
BMC Complement Altern Med. 2018-2-17
Medicine (Baltimore). 2020-12-4
Evid Based Complement Alternat Med. 2013-5-13
Medicine (Baltimore). 2025-5-2
Front Pharmacol. 2025-3-4
Comb Chem High Throughput Screen. 2025